New York, Jan 7, 2026, 12:14 PM EST — Regular session
- Apellis shares were up about 8% midday, building on a volatile start to the year for biotech stocks
- The company is due to present at the J.P. Morgan Healthcare Conference on Jan. 12
- Investors are watching for any commercial and pipeline updates on Syfovre and Empaveli
Apellis Pharmaceuticals shares rose nearly 8% on Wednesday, outperforming the broader market as traders positioned ahead of the company’s scheduled appearance at next week’s J.P. Morgan Healthcare Conference. 1
The Waltham, Massachusetts-based drugmaker said on Monday it will present on Jan. 12 at 11:15 a.m. PT, with a live webcast posted to its investor site and a replay available afterward. Big healthcare conferences often bring fresh guidance, new trial details or partnering chatter — and the tape tends to price that in early. 1
Apellis was last up $1.91 at $25.85 in midday trading, after touching $25.89. The stock opened at $24.02 and traded as low as $24.05, according to market data.
The company markets Syfovre, an eye injection for geographic atrophy — an advanced form of age-related macular degeneration that can lead to irreversible vision loss — and Empaveli for a rare blood disease called paroxysmal nocturnal hemoglobinuria. Competitive pressure and demand trends for Syfovre have been the key swing factors for the stock over the past year. 2
Apellis also posted recent insider reporting to the SEC, including Form 4 filings tied to equity awards. Those filings are common in early January and do not necessarily signal a change in executives’ views, but they can draw attention when a stock is moving. 3
What investors are watching next is simple: whether Apellis uses the JPM stage to sharpen its outlook on demand for Syfovre, update payor access and safety monitoring, or outline next steps for its pipeline. Any shift in tone — even without new numbers — can move a name that’s been this headline-sensitive. 1
There’s a clear “but” for bulls: the geographic atrophy market is competitive, and Syfovre’s uptake has been scrutinized closely since launch. Any sign of slower prescriptions, tougher reimbursement, or safety worries resurfacing could cap the rally quickly. 2
